Pharmacy Times August 8, 2024
Ashley Gallagher, Associate Editor

Denileukin diftitox-cxdl is the only therapy approved for cutaneous T-cell lymphoma that targets IL-2 receptors in malignant T-cells and Tregs.

The FDA approved denileukin diftitox-cxdl (Lymphir; Citius Pharmaceuticals), a novel immunotherapy, for the treatment of relapsed or refractory (R/R) cutaneous T-cell lymphoma (CTCL) after at least 1 prior systemic therapy. This is the only CTCL therapy that targets IL-2 receptors in malignant T-cells and Tregs and is the first indication for denileukin diftitox-cxdl.1

“As a treating oncologist, I have seen the profound negative effect on the quality of life in patients with R/R CTCL,” said Francine Foss, MD, professor of hematology and director of the Multidisciplinary T-cell Lymphoma Program at Yale Cancer Center, in a news release. “Given the long-term...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

Continue Reading

 
Topics: Biotechnology, FDA, Govt Agencies, Pharma / Biotech
Related Articles:
Marty Makary, Who Made His Name Bashing the Medical Establishment, May Soon Lead FDA
Gutting FDA Won't Make America Healthy
Google’s Pixel Watch 3 Loss of Pulse Detection Feature Receives FDA Clearance
FDA Annual Flu Vaccine Meeting and CDC’s ‘Wild to Mild’ Campaign Canceled
Supporting the Development of Drugs for Rare Diseases — The Importance of Regulatory Transparency

Share This Article